Grasp the latest information from Olin and understand the new trends in the industry.
On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-
Recently, the China National Intellectual Property Administration issued the Notice on Determining the Demonstration Creation Objects for the Construction of a National Intellectual Property Powerhouse (2025-2027). Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was successfully selected as a “National Intellectual Property Demonstration Enterprise Creation Object” by virtue of its systematic layout and outstanding achievements in the comprehensive management of in
On September 28, the Chengdu Industrial Boutique Release & Supply-Demand Matching Conference with the theme of “Supply-Demand Collaboration, Co-creating Boutiques” was grandly held in Chengdu. The Haemophilus influenzae type b conjugate vaccine (Hib vaccine) of Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was honorably selected and successfully included in the new list of “Chengdu Industrial Boutiques”.
On September 8, 2025, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) and Jiangsu Provincial Center for Disease Control and Prevention (hereinafter referred to as “Jiangsu Provincial CDC”) officially signed a strategic cooperation framework agreement in Chengdu. Centered on the core principles of “Technology-
Recently, the Recombinant Five-antigen Staphylococcus Aureus Vaccine (rFSAV), a Class 1.1 New Drug co-developed by Chengdu Olymvax Biopharmaceuticals Inc.
On April 2, 2025, Mr. Fabio Schina, Consul General of Italy in Chongqing, and his entourage visited Olymvax and had in-depth exchanges with the Company’s senior management on the cooperation prospects in the biomedical field.